drug summary · 2 NDC codes
FOUNDAYO 17.2 mg/1
orforglipron
HUMAN PRESCRIPTION DRUG record from the RxAtlas dataset, marketing status NDA. Facts and NDC codes below are exported values from the current release, not inferred or edited prose.
Facts
Field definitions, types, and provenance rules are in the data dictionary.
| generic name | orforglipron |
|---|---|
| active ingredients | ORFORGLIPRON CALCIUM |
| dosage form | TABLET, FILM COATED |
| route | ORAL |
| strength | 17.2 mg/1 |
| marketing status | NDA |
| DEA schedule | not reported |
| application number | NDA220934 |
| ATC code | not reported |
| RxCUI | not reported |
| manufacturer | Eli Lilly and Company |
| product type | HUMAN PRESCRIPTION DRUG |
| pharmacologic class | Decreased Gastric Motility [PE]; GLP-1 Receptor Agonist [EPC]; Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]; Increased Gastric Muscle Tone [PE] |
NDC codes
2 National Drug Codes are mapped to this product in the current release. Package descriptions are not part of the published export, so the NDC code is the canonical package identifier here.
| NDC | Package description |
|---|---|
| 00002495331 | — |
| 0002-4953 | — |
Other orforglipron products
5 other products in the current release publish the same generic name. Strength, dosage form, and labeler are what distinguish them.
- FOUNDAYO .8 mg/1TABLET, FILM COATED · Eli Lilly and Company
- FOUNDAYO 14.5 mg/1TABLET, FILM COATED · Eli Lilly and Company
- FOUNDAYO 2.5 mg/1TABLET, FILM COATED · Eli Lilly and Company
- FOUNDAYO 5.5 mg/1TABLET, FILM COATED · Eli Lilly and Company
- FOUNDAYO 9 mg/1TABLET, FILM COATED · Eli Lilly and Company
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access to the full catalogue; credited toward the licence.